Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
- Resource Type
- Article
- Authors
- Goetz, M.P.; Bagegni, N.A.; Batist, G.; Brufsky, A.; Cristofanilli, M.A.; Damodaran, S.; Daniel, B.R.; Fleming, G.F.; Gradishar, W.J.; Graff, S.L.; Grosse Perdekamp, M.T.; Hamilton, E.; Lavasani, S.; Moreno-Aspitia, A.; O’Connor, T.; Pluard, T.J.; Rugo, H.S.; Sammons, S.L.; Schwartzberg, L.S.; Stover, D.G.; Vidal, G.A.; Wang, G.; Warner, E.; Yerushalmi, R.; Plourde, P.V.; Portman, D.J.; Gal-Yam, E.N.
- Source
- In Annals of Oncology December 2023 34(12):1141-1151
- Subject
- Breast tumor
- Language
- ISSN
- 0923-7534